PRISM Pharma Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: C-82 Topical Gel, 1%Drug: C-82 Topical Gel, PlaceboDrug: Daivonex creamDrug: Diprosis gel
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02432027
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Phase 1
Completed
- Conditions
- Systemic Scleroderma
- Interventions
- Drug: C-82 Topical Gel, PlaceboDrug: C-82 Topical Gel, 1%
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT02349009
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Phase 1
Completed
- Conditions
- Pancreatic AdenocarcinomaMetastatic Pancreatic CancerAdvanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01764477
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT01606579
- Locations
- 🇺🇸
University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸Emory University / Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT01302405
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Department of Oncology, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath